Stocks · News reference
AbbVie reported positive Phase 3 LUNA study results for atogepant, proving its efficacy and safety in preventing menstrual migraines.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
President Trump's Surgeon General nominee Dr. Nicole Saphier disclosed investments in Philip Morris and other companies, agreeing to divest if confirmed.
Vanguard's VHT and State Street's XPH offer different approaches to healthcare investing. VHT provides broad sector exposure with lower costs (0.09% expense ratio) and higher dividend yield (1.5%), making it ideal for long-term investors. XPH focuses on pharmaceuticals with higher volatility but stronger 1-year returns (57.2% vs 29.3%), appealing to growth-oriented investors willing to accept greater risk.
HSBC analyst Rajesh Kumar maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $300 to $315.